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Abstract Herpes simplex virus type 1 (HSV-1) encephalitis
causes a deleterious inflammation and elevated intracranial
pressure. As a step towards examining the origin of the in-
flammation, we here report the response of circulating
proteasomes and complement factors in blood and cerebrospi-
nal fluid (CSF) in rats infected with HSV-1. Infection was via
the nasal route, with 1.1 × 104 plaque-forming units of HSV-1
strain 2762 given in one or both nostrils. A sandwich enzyme-
linked immunosorbent assay was used to study the level of
26S proteasomes and their complex formation with comple-
ment factors 3 and 4. HSV-1 infection in the rat causes a
complex formation between complement factors and
proteasomes, which we designate compleasomes. In the first
experiment, with HSV-1 given in both nostrils, compleasomes
containing complement factors 3 and 4 increased significantly
in both blood plasma and CSF. The concentration of
proteasomes in plasma was similar in controls and infected
rats (320 ± 163 vs. 333 ± 125 ng/ml). In the second experi-
ment, with HSV-1 given in one nostril, CSF levels were
1 ± 1 ng/ml in controls and 56 ± 22 ng/ml in the HSV-1 group,
whereas the total protein concentration in CSF remained the
same in the two groups. The compleasome response was lim-
ited to CSF, with a highly significant difference between in-
fected rats and controls (n = 11, p < 0.001). It was possible to
mimic the reaction between proteasomes and complements 3
and 4 in vitro in the presence of ATP.
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Introduction
Herpes simplex virus type 1 (HSV-1), a usually benign virus
that commonly causes recurrent oral lesions, may occasionally
induce a necrotizing encephalitis focused on the frontotemporal
regions of the brain. The pathogenetic factors responsible for
HSV-1 encephalitis (HSE) in adults are obscure, and although
antiviral treatment with acyclovir has significantly reduced the
mortality (Sköldenberg et al. 1984), most patients suffer from
neurological sequels at follow-up (Raschilas et al. 2002,
Hjalmarsson et al. 2007). A prolonged intrathecal inflammato-
ry response including activation of the complement system has
been documented in HSE patients (Aurelius et al. 1993,
Aurelius et al. 1994, Eriksson et al. 2016).
The ubiquitin-proteasome pathway degrades defective and
foreign proteins and plays an important role in a wide variety
of cell functions including antigen processing, transcription
regulation, cell cycle regulation, and DNA repair. This system
is manipulated by a variety of viruses, including HSV-1 (Gao
and Luo 2006). The ICP0 protein expressed by HSV-1 is a
ubiquitin ligase which promotes the spread of the virus by
degrading various cellular proteins (Boutell and Everett
2013). Most proteasomes are located intracellularly, but circu-
lating proteasomes have also been found extracellularly in
blood and other body fluids including cerebrospinal fluid
(CSF) (Sixt and Dahlmann 2008, Mueller et al. 2012).
We have previously shown that a peptide derived from the
proteasome subunit antisecretory factor (AF) abolishes sick-
ness and death in rats subjected to experimental HSE
(Jennische et al. 2008). This counteraction of the lethal en-
cephalitis is most likely accomplished by lowering the
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intracranial pressure. Diet-induced antisecretory factor has al-
so been shown to prevent intracranial hypertension
(Johansson et al. 2013). In order to reveal the mechanism
behind this effect, we isolated a precursor of the antisecretory
factor in blood, consisting of a complex of circulating
proteasomes and complement factor 3 (C3) (Lonnroth et al.
2016). During formation of the complex, C3 was split into
C3c, which changed the proteasome conformation to expose
the hidden antisecretory peptide.
In the present study, we found that HSV-1 is able to induce
similar complexes of proteasomes and complement factors 3
and 4 (C3 and C4). However, no hydrolyses of C3 or exposure
of AF occurred in this complex. As a general designation of
the complex between complement factors and proteasomes,
we here introduce the term Bcompleasome^.
Materials and methods
General reagents
Monoclonal antibody against AF/RPN10 was produced as pre-
viously described (Johansson et al. 2009). Monoclonal mouse
IgG antibodies against proteasome LMP2 (20Sβ1i), 20Sα6,
ubiquitin and the proteasome 26S and 20S proteins were ob-
tained from Enzo Life Sciences Inc. (www.enzolifesciences.
com). Polyclonal antibody against proteasome 19S subunit
was produced as previously described (Lonnroth et al. 2016);
polyclonal antibodies against C3 and C4 were obtained from
Dako (www.dako.com, items A0062 and Q0369). Secondary
antibodies, alkaline phosphatase conjugated goat anti-rabbit
IgG and goat anti-mouse IgM were obtained from Jackson
ImmunoResearch Laboratories, Inc.
Animal model
Male Sprague-Dawley rats with body weight 250 ± 20 g
(Nova-SCB, Sollentuna, Sweden) were used. The regional
ethical committee of the University of Gothenburg approved
the study protocol, and all experiments were performed in
accordance with the guidelines for animal experiments (EC
Directive 86/609/EEC). The rats were allowed a week for
general adaptation in their cages before the experiments and
had free access to water and pelleted food during the experi-
ments. The temperature and ventilation in the animal quarters
were monitored according to standard procedures. The ani-
mals were infected with HSV-1 strain 2762, originally isolated
from the brain of a patient with HSE, in the nostril under
isoflurane anaesthesia as previously described (Jennische
et al. 2015). In the first experiment, a 25 μl dose containing
1.1 × 104 plaque-forming units of HSV-1 was given in each
nostril to 6 rats; 5 controls receiving phosphate buffered saline
(PBS; pH 7.2) were used. In the second experiment, one dose
of 1.1 × 104 plaque-forming units was given in the right nostril
to 11 rats (12 controls receiving PBS were used). The animals
were sacrificed at day 5 before development of clinical symp-
toms as elaborated in previous experiments (Jennische et al.
2015). For ethical reasons, the extent of the experiment could
not exceed day 5, at which time the animals began to show
symptoms of neurological dysfunction, i.e. repetitive, stereo-
typic movements and motor instability.
Blood and CSF sampling
The rats were brought to deep anaesthesia with isoflurane
(Forane, Baxter, Deerfield, IL) before the sampling took place.
Blood The heart was punctured from the right thoracic cavity
with an injection needle (OD 1.22 mm, length 60 mm).
Following this, 10–12 ml of blood was drawn during 2–
3 min and immediately mixed with heparin in order to avoid
coagulation. The blood was centrifuged at 1200×g for 15 min,
and then the plasma was mixed with an equal volume of cit-
rate buffer (glucose 0.11 M, tri-sodium-citrate 0.03 M and
sodium chloride 0.07 M; pH 6.1). Each sample was subse-
quently divided into 2 ml aliquots and kept at −20 °C until
use. No sample was stored frozen for more than 4 weeks.
CSFAfter termination of the rat by removal of the heart, the
rat was placed on its abdomen and the neck muscles were
laterally dissected to expose the midline of the dura over the
cisterna magna. This line was used as a marker for puncture in
order to reach CSF in the underlying cisterna magna, using a
neoflon i.v. cannula (OD 0.6 mm, length 19 mm). After dura
puncture, the needle was inserted a further 3–5 mm and then
removed from the surrounding plastic cannula. This allowed
50–200 μl of CSF to be aspired from the cisterna magna
without being contaminated with blood. The CSF was centri-
fuged at 1200×g for 5 min and the supernatant subsequently
diluted with an equal volume of the citrate buffer (pH 6.1).
Each sample was kept at −20 °C until use.
Compleasome ELISA
A sandwich enzyme-linked immunosorbent assay (ELISA)
for detection of compleasomes (proteasome/complement
complexes) in blood plasma and liquor was performed as pre-
viously described (Lonnroth et al. 2016). Monoclonal anti-
bodies (mab) against proteasome proteins subunits, or PBS
as control were coated on a Nunc 96-well MaxiSorp polyvinyl
plate (Sigma-Aldrich) overnight (dilution 1:2000 except mab
AF1 which was diluted 1:400). After blocking with 0.2%
bovine serum albumin (BSA) at 37 °C for 45 min, plasma
and CSF samples were titrated in PBS with 0.2% BSA and
0.05% Tween 20, and shaken for 1 h. A polyclonal rabbit
antibody (anti-C3 or anti-C4) at 1:2000 dilution was applied
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as detecting antibody. An anti-rabbit-alkaline phosphatase
(AP) secondary antibody was applied after 30 min of incuba-
tion, and AP substrate was added after a further 30 min.
Absorbance was read at 405 nm in a photometer, and the
difference between antibody-coated samples and controls
(PBS) was estimated.
Proteasome ELISA
A sandwich ELISA detection of 26S proteasomes was per-
formed as previously described (Lonnroth et al. 2016). Since
the proteasome proteins in mammals are extremely conserved,
the antibodies against the human and rat proteins cross-react.
Capturing antibodies against 20Sα6 diluted 1:1000 were coat-
ed on a Nunc 96-well MaxiSorp, and the polyclonal anti-19S
proteasome subunit, diluted 1:400, was used as detecting an-
tibody. 26S proteasome (Enzo Life Sciences) was used as
reference and rabbit pre-immune serum as control. The same
protocol was used as previously described for compleasome
ELISA.
In vitro experiments
Proteasomes together with C3 and C4 were incubated in PBS
containing 1 mMATP (Sigma-Aldrich) at 37 °C for 3 h. Three
experiments were performed with similar results. After
incubation, the samples were frozen and kept at −20 °C until
testing with compleasome ELISA.
Protein determination
The protein content in CSF was determined with the Pierce
BCA protein assay kit (Thermo Scientific) using a NanoDrop
photometer from Saveen Werner.
Statistics
Data are presented as mean ± SEM. Statistical significance of
difference (p value) for two means was assessed using an




In the first experiment, the rats were infected with HSV-1 in
both nostrils, causing a systemic infection. The experiment
was ended at day 5, at which time the animals began to show
symptoms of neurological dysfunction, but before the appear-
ance of severe clinical symptoms of encephalitis. Preliminary
experiments on rats infected with HSV-1 showed that an
Fig. 1 Rats after 5 days of
intranasal challenge with herpes
virus type 1 (HSV-1, n = 6) or
phosphate-buffered saline as





proteasomes as catching antibody
and polyclonal antibodies (pcl)
against complement factors 3 and
4 (C3 and C4) as detecting
antibodies. a Compleasomes in
plasma and liquor detected with
mab against proteasome subunits
20Sα6 and pcl against C3. The
infected animals had significantly
higher values than controls
(p < 0.05 in plasma, p < 0.01 in
CSF). b Plasma samples, mab
against proteasome subunits
LMP2 and 20Sα6 versus pcl
against C3 or C4 as detecting
antibody (HSV vs. controls
p < 0.01 in both cases)
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aggregation of proteasomes and C3 into compleasomes oc-
curred at day 5 but not at day 4. Both blood plasma and
CSF showed a significant increase in compleasomes when
measured with antibodies against the proteasome subunit
20Sα6 and C3 (Fig. 1a). The response at day 5 was more
pronounced in CSF than in blood, the ratios between test
and control being 7.4 (p < 0.01) and 3.3 (p < 0.05), respec-
tively. The monoclonal antibody against the exposed protea-
some subunits LMP2 also revealed a pronounced
compleasome response in plasma (p < 0.01, Fig. 1b). In con-
trast, antibodies against the hidden proteasome subunit AF1/
Rpn10 or the non-proteasome protein ubiquitin gave no sig-
nificant response (not shown). This suggests that the
compleasome is intact and involves neither antisecretory fac-
tor nor ubiquitin.
As shown in Fig. 1b, C4-containing compleasomes were
also increased in blood (p < 0.05). C3 and C4 are able to form
complexes with each other, and such a complex might occur
in the compleasome. The concentration of circulating
proteasomes in blood plasma was not changed, being
320 ± 163 ng/ml in controls and 333 ± 125 ng/ml in infected
rats. This is in the same range as the proteasome concentration
in human plasma (Sixt and Dahlmann 2008).
One-sided infection
In the second experiment, the rats were infected with HSV-1
in only one nostril. During this condition, the compleasome
response was seen in CSF but no response was achieved in
blood. The protein concentration in CSF was similar in the
controls and the HSV-1 group, being 1.10 ± 0.25 and
1.32 ± 0.14 mg/ml, respectively. There thus seems not to have
been any general leakage of proteins from blood to CSF in the
infected animals. There were only barely detectable levels of
proteasomes in CSF of the control rats (1 ± 1 ng/ml), whereas
the HSV-1 group contained a relatively high level
(56 ± 22 ng/ml). The significant rise of proteasomes must
therefore have been caused by the HSV-1 infection, and
most of the proteasomes might be bound in the
compleasomes. The level of proteasomes in the infected
animals was similar to that found by Mueller et al. (2012) in
CSF of patients treated for spinal canal stenosis. Those authors
also found no correlation between the content of proteasomes
and interleukin 6, indicating that proteasomes might be
formed in CSF without being initiated by an inflammatory
reaction.
In previous experiments on the same rat model HSV-1 was
infected via one nostril (Jennische et al. 2015), the virions and
inflammation were shown to be initially localized exclusively
in one brain half before spreading via the olfactory bulb to the
other half. It is clear that the virions cause a local infection
under these conditions, in contrast to the systemic infection
achieved after administration in both nostrils.
The proteasomes in CSF were bound to both C3 (Fig. 2a)
and C4 (Fig. 2b) and showed a pronounced increase in both
cases, with test/control ratios of 20 (p < 0.001) and 7
(p < 0.001), respectively. Thus, there was a concomitant ag-



































Fig. 2 Cerebrospinal fluid (CSF) of rats after 5 days of challenge with
herpes virus type 1 (HSV-1, n = 11) or phosphate buffered saline as
control (CTR, n = 12). Sandwich enzyme-linked immunosorbent assay
with monoclonal antibodies against proteasome 20Sα6 subunit as
catching antibody and polyclonal antibodies against complement factor
3 (2A) or complement factor 4 (2B) as detecting antibody. The infected
rats showed significantly higher values than controls (p < 0.001)
Table 1 In vitro test of compleasome reactions
C3 C4
26S 0 0
26S + C3 0.09 0
26S + C3 + C4 0.30 0.81
20S 0 0
20S + C3 + C4 0.28 0.63
Incubation of 26S proteasomes and complement factors 3 and 4 (C3 and
C4) for 3 h at 37 °C. The formation of compleasome complexes was
assayed by sandwich enzyme-linked immunosorbent assay using
20Sα6 as catching antibody and anti C3 or C4 as detecting antibody.
All proteins were in equimolar concentration (20 nM). The values given
here are absorbance at 405 nm at 1/3 dilution
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suggest a co-localization of C3 and C4 in the compleasome.
Interestingly, both C3 and C4 are involved in the recently
discovered degradation of viral particles by intracellular
proteasomes (Tam et al. 2014). The deposition and covalent
attachment of complement factors onto pathogens results in its
translocation into cells during infection, in which it simulta-
neously induces an antiviral state and directs the degradation
of virus particles. This finding suggests that also the extracel-
lular interaction between C3, C4 and proteasomes is initially
involved in virus degradation.
The complement factors are produced locally in the brain,
and during HSV-1 infection a general complement activation
is achieved intrathecally (Orsini et al. 2014, Eriksson et al.
2016). This activation probably contributes to the high intra-
cranial pressure during encephalitis. Intranasal administration
of the proteasomal AF-16 peptide has been shown to decrease
intracranial pressure, completely abolishing the development
of clinical symptoms in the rat model (Jennische et al. 2008).
The mechanism of this action is unknown but is probably
connected to the formation of compleasomes.
In vitro test of compleasome formation
In order to study the formation of compleasomes in vitro,
proteasomes and complement factors were incubated in a
physiological phosphate buffer containing ATP. As seen in
Table 1, the proteasomes alone gave no significant re-
sponse. In contrast, the proteasomes and complement fac-
tors together gave a response both with 26S proteasomes
and with the catalytic portion 20S. The fact that controls
with albumin or IgG antibodies gave no reaction suggests
that the proteasomes catalysed the reaction rather than act-
ing as passive recipients of complement factors.
The role of extracellular proteasomes is not known.
However, they are enzymatically active in CSF, which suggests
that they are able to remove defective proteins in the same way
as in cells (Mueller et al. 2012). The virus ring finger protein
ICP0 binds to proteasomes and manipulates their degradation
of proteins and might be involved in the compleasome forma-
tion. Our previous studies showed that a specific part of the
proteasome subunit AF/RPN10 inhibited the lethal intracranial
pressure during HSE (Jennische et al. 2008). The AF protein is
exposed and possibly released during degradation of
compleasomes (Lonnroth et al. 2016). This degradation was
not achieved in the present study, but might occur during the
later course of the infection. The HSV-1 induced rise of
proteasomes and their reaction with complement factors imply
that they are a part of the innate immune system. In conclusion,
HSV-1 induces complex formation of proteasomes and com-
plement factors 3 and 4 in a reaction which could be mimicked
in vitro. Whether this response is beneficial or destructive re-
mains to be seen.
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